Physician attitudes about genetic testing for localized prostate cancer: A national survey of radiation oncologists and urologists

Simon P. Kim, Neal J. Meropol, Cary P. Gross, Jon C Tilburt, Badrinath Konety, James B. Yu, Robert Abouassaly, Christopher J. Weight, Stephen B. Williams, Nilay D Shah

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Genetic testing has been recently put forth as a strategy to improve decision-making in the management of localized prostate cancer. Little is known about how frequently prostate cancer specialists are using these tests, or whether they consider them important or effective. We performed a national survey of radiation oncologists and urologists on their perceptions and self-reported use of genetic testing. Methods: From January to July 2017, a 4-wave mail survey was performed involving 915 radiation oncologists and 940 urologists about genetic testing and decision-making for localized prostate cancer. The survey queried the frequency and type of genetic test and the degree of importance and confidence of such tests. Pearson chi-square and multivariable logistic regression analyses were performed to identify respondent characteristics associated with outcomes. Results: Overall response rate was 37.3% (n = 691). One in six specialists reported frequently using genetic tests with urologists more likely than radiation oncologists to do so (26% vs. 4%; OR: 3.51, p < 0.001) and their perceived higher importance (46% vs. 20%; adjusted OR: 3.51, p < 0.001) as well as their confidence in doing so (70% vs. 39%; OR: 3.81, p < 0.001) for decision-making for localized prostate cancer. Prolaris and Oncotype represented the most commonly cited tumor-based genetic testings. Conclusions: Few radiation oncologists and urologists report frequently using genetic testing for treatment decision-making among patients diagnosed with localized prostate cancer, though more urologists use these tests and believe they yield meaningful results.

Original languageEnglish (US)
JournalUrologic Oncology: Seminars and Original Investigations
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Genetic Testing
Prostatic Neoplasms
Physicians
Decision Making
Postal Service
Logistic Models
Regression Analysis
Surveys and Questionnaires
Radiation Oncologists
Urologists
Neoplasms

Keywords

  • Biomarkers
  • Genetic testing
  • Genomics
  • Overtreatment
  • Prostate cancer
  • Survey
  • Treatment recommendations

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Physician attitudes about genetic testing for localized prostate cancer : A national survey of radiation oncologists and urologists. / Kim, Simon P.; Meropol, Neal J.; Gross, Cary P.; Tilburt, Jon C; Konety, Badrinath; Yu, James B.; Abouassaly, Robert; Weight, Christopher J.; Williams, Stephen B.; Shah, Nilay D.

In: Urologic Oncology: Seminars and Original Investigations, 01.01.2018.

Research output: Contribution to journalArticle

Kim, Simon P. ; Meropol, Neal J. ; Gross, Cary P. ; Tilburt, Jon C ; Konety, Badrinath ; Yu, James B. ; Abouassaly, Robert ; Weight, Christopher J. ; Williams, Stephen B. ; Shah, Nilay D. / Physician attitudes about genetic testing for localized prostate cancer : A national survey of radiation oncologists and urologists. In: Urologic Oncology: Seminars and Original Investigations. 2018.
@article{80a829d0851542d786e1098808973ffb,
title = "Physician attitudes about genetic testing for localized prostate cancer: A national survey of radiation oncologists and urologists",
abstract = "Introduction: Genetic testing has been recently put forth as a strategy to improve decision-making in the management of localized prostate cancer. Little is known about how frequently prostate cancer specialists are using these tests, or whether they consider them important or effective. We performed a national survey of radiation oncologists and urologists on their perceptions and self-reported use of genetic testing. Methods: From January to July 2017, a 4-wave mail survey was performed involving 915 radiation oncologists and 940 urologists about genetic testing and decision-making for localized prostate cancer. The survey queried the frequency and type of genetic test and the degree of importance and confidence of such tests. Pearson chi-square and multivariable logistic regression analyses were performed to identify respondent characteristics associated with outcomes. Results: Overall response rate was 37.3{\%} (n = 691). One in six specialists reported frequently using genetic tests with urologists more likely than radiation oncologists to do so (26{\%} vs. 4{\%}; OR: 3.51, p < 0.001) and their perceived higher importance (46{\%} vs. 20{\%}; adjusted OR: 3.51, p < 0.001) as well as their confidence in doing so (70{\%} vs. 39{\%}; OR: 3.81, p < 0.001) for decision-making for localized prostate cancer. Prolaris and Oncotype represented the most commonly cited tumor-based genetic testings. Conclusions: Few radiation oncologists and urologists report frequently using genetic testing for treatment decision-making among patients diagnosed with localized prostate cancer, though more urologists use these tests and believe they yield meaningful results.",
keywords = "Biomarkers, Genetic testing, Genomics, Overtreatment, Prostate cancer, Survey, Treatment recommendations",
author = "Kim, {Simon P.} and Meropol, {Neal J.} and Gross, {Cary P.} and Tilburt, {Jon C} and Badrinath Konety and Yu, {James B.} and Robert Abouassaly and Weight, {Christopher J.} and Williams, {Stephen B.} and Shah, {Nilay D}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.urolonc.2018.07.002",
language = "English (US)",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Physician attitudes about genetic testing for localized prostate cancer

T2 - A national survey of radiation oncologists and urologists

AU - Kim, Simon P.

AU - Meropol, Neal J.

AU - Gross, Cary P.

AU - Tilburt, Jon C

AU - Konety, Badrinath

AU - Yu, James B.

AU - Abouassaly, Robert

AU - Weight, Christopher J.

AU - Williams, Stephen B.

AU - Shah, Nilay D

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: Genetic testing has been recently put forth as a strategy to improve decision-making in the management of localized prostate cancer. Little is known about how frequently prostate cancer specialists are using these tests, or whether they consider them important or effective. We performed a national survey of radiation oncologists and urologists on their perceptions and self-reported use of genetic testing. Methods: From January to July 2017, a 4-wave mail survey was performed involving 915 radiation oncologists and 940 urologists about genetic testing and decision-making for localized prostate cancer. The survey queried the frequency and type of genetic test and the degree of importance and confidence of such tests. Pearson chi-square and multivariable logistic regression analyses were performed to identify respondent characteristics associated with outcomes. Results: Overall response rate was 37.3% (n = 691). One in six specialists reported frequently using genetic tests with urologists more likely than radiation oncologists to do so (26% vs. 4%; OR: 3.51, p < 0.001) and their perceived higher importance (46% vs. 20%; adjusted OR: 3.51, p < 0.001) as well as their confidence in doing so (70% vs. 39%; OR: 3.81, p < 0.001) for decision-making for localized prostate cancer. Prolaris and Oncotype represented the most commonly cited tumor-based genetic testings. Conclusions: Few radiation oncologists and urologists report frequently using genetic testing for treatment decision-making among patients diagnosed with localized prostate cancer, though more urologists use these tests and believe they yield meaningful results.

AB - Introduction: Genetic testing has been recently put forth as a strategy to improve decision-making in the management of localized prostate cancer. Little is known about how frequently prostate cancer specialists are using these tests, or whether they consider them important or effective. We performed a national survey of radiation oncologists and urologists on their perceptions and self-reported use of genetic testing. Methods: From January to July 2017, a 4-wave mail survey was performed involving 915 radiation oncologists and 940 urologists about genetic testing and decision-making for localized prostate cancer. The survey queried the frequency and type of genetic test and the degree of importance and confidence of such tests. Pearson chi-square and multivariable logistic regression analyses were performed to identify respondent characteristics associated with outcomes. Results: Overall response rate was 37.3% (n = 691). One in six specialists reported frequently using genetic tests with urologists more likely than radiation oncologists to do so (26% vs. 4%; OR: 3.51, p < 0.001) and their perceived higher importance (46% vs. 20%; adjusted OR: 3.51, p < 0.001) as well as their confidence in doing so (70% vs. 39%; OR: 3.81, p < 0.001) for decision-making for localized prostate cancer. Prolaris and Oncotype represented the most commonly cited tumor-based genetic testings. Conclusions: Few radiation oncologists and urologists report frequently using genetic testing for treatment decision-making among patients diagnosed with localized prostate cancer, though more urologists use these tests and believe they yield meaningful results.

KW - Biomarkers

KW - Genetic testing

KW - Genomics

KW - Overtreatment

KW - Prostate cancer

KW - Survey

KW - Treatment recommendations

UR - http://www.scopus.com/inward/record.url?scp=85053062861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053062861&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2018.07.002

DO - 10.1016/j.urolonc.2018.07.002

M3 - Article

C2 - 30190177

AN - SCOPUS:85053062861

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

ER -